P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain disposition and oral availability of the novel taxane cabazitaxel (jevtana) in mice

Molecular Pharmaceutics

Volumn 12, Issue 10, 2015, Pages 3714-3723

  Tang, Seng Chuan ^a   Kort, Anita ^a   Cheung, Ka Lei ^b   Rosing, Hilde ^a   Fukami, Tatsuki ^c   Durmus, Selvi ^a   Wagenaar, Els ^a   Hendrikx, Jeroen J M A ^a   Nakajima, Miki ^c   Van Vlijmen, Bart J M ^b   Beijnen, Jos H ^a,d   Schinkel, Alfred H ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c KANAZAWA UNIVERSITY   (Japan)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Brain accumulation; Cabazitaxel; Carboxylesterase; P glycoprotein; Pharmacokinetics

Indexed keywords

CABAZITAXEL; CARBOXYLESTERASE; CYTOCHROME P450 3A; ELACRIDAR; MULTIDRUG RESISTANCE PROTEIN; RITONAVIR; ANTINEOPLASTIC AGENT; CARBOXYLESTERASE 1, MOUSE; TAXOID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG DISPOSITION; DRUG TRANSPORT; ENZYME INHIBITION; IN VITRO STUDY; IN VIVO STUDY; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BLOOD LEVEL; UPREGULATION; ANIMAL; BLOOD; BRAIN CHEMISTRY; DOG; MDCK CELL LINE; METABOLISM; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN CHEMISTRY; CARBOXYLESTERASE; CARBOXYLIC ESTER HYDROLASES; CYTOCHROME P-450 CYP3A; DOGS; MADIN DARBY CANINE KIDNEY CELLS; MALE; MICE; MICE, KNOCKOUT; P-GLYCOPROTEIN; TAXOIDS;

EID: 84977127892     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/acs.molpharmaceut.5b00470     Document Type: Article

References (42)

1. Tkaczuk, K. H., Yared, J. A. Update on taxane development: new analogs and new formulations. DrugDes., Dev. Ther. 2012, 6, 371-384.
2. Gottesman, M. M., Fojo, T., Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
3. Petrylak, D. P., Tangen, C. M., Hussain, M. H., Lara, P. N., Jr., Jones, J. A., Taplin, M. E., Burch, P. A., Berry, D., Moinpour, C., Kohli, M., Benson, M. C., Small, E. J., Raghavan, D., Crawford, E. D. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004, 351, 1513-1520.
4. Seruga, B., Ocana, A., Tannock, I. F. Drug resistance in metastatic castration-resistant prostate cancer. Nat. Rev. Clin. Oncol. 2011, 8, 12-23.
5. Center for Drug Evaluation and Research of the US Department of Health and Human Services. Clinical Pharmacology and Biopharmaceutics Review(s): Jevtana, 2010. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2010/201023s000ClinPharmR.pdf (accessed February 13, 2015).
6. European Medicines Agency. Assessment Report for Jevtana, 2011. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002018/WC500104766.pdf (accessed February 13, 2015).
7. Cisternino, S., Bourasset, F., Archimbaud, Y., Semiond, D., Sanderink, G., Scherrmann, J. M. Nonlinear accumulation in the brain of the new taxoid TXD258 following saturation of P-glycoprotein at the blood-brain barrier in mice and rats. Br. J. Pharmacol. 2003, 138, 1367-1375.
8. de Bono, J. S., Oudard, S., Ozguroglu, M., Hansen, S., Machiels, J. P., Kocak, I., Gravis, G., Bodrogi, I., Mackenzie, M. J., Shen, L., Roessner, M., Gupta, S., Sartor, A. O. Investigators, T. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010, 376, 1147-1154.
9. Vrignaud, P., Semiond, D., Lejeune, P., Bouchard, H., Calvet, L., Combeau, C., Riou, J. F., Commercon, A., Lavelle, F., Bissery, M. C. Preclinical antitumor activity of cabazitaxel, a semisynthetic taxane active in taxane-resistant tumors. Clin. Cancer Res. 2013, 19, 2973-2983.
10. Sarantopoulos, J., Mita, A. C., Wade, J. L., Morris, J. C., Rixe, O., Mita, M. M., Dedieu, J. F., Wack, C., Kassalow, L., Lockhart, A. C. Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. Cancer Chemother. Pharmacol. 2014, 74, 1113-1124.
11. Koolen, S. L., Beijnen, J. H., Schellens, J. H. Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel. Clin. Pharmacol. Ther. 2010, 87, 126-129.
12. Moes, J., Koolen, S., Huitema, A., Schellens, J., Beijnen, J., Nuijen, B. Development of an oral solid dispersion formulation for use in low-dose metronomic chemotherapy of paclitaxel. Eur. J. Pharm. Biopharm. 2013, 83, 87-94.
13. Stuurman, F. E., Nuijen, B., Beijnen, J. H., Schellens, J. H. Oral anticancer drugs: mechanisms of low bioavailability and strategies for improvement. Clin. Pharmacokinet. 2013, 52, 399-414.
14. Hendrikx, J. J., Lagas, J. S., Wagenaar, E., Rosing, H., Schellens, J. H., Beijnen, J. H., Schinkel, A. H. Oral co-administration of elacridar and ritonavir enhances plasma levels of oral paclitaxel and docetaxel without affecting relative brain accumulation. Br. J. Cancer 2014, 110, 2669-2676.
15. Hendrikx, J. J., Lagas, J. S., Rosing, H., Schellens, J. H., Beijnen, J. H., Schinkel, A. H. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel. Int. J. Cancer 2013, 132, 2439-2447.
16. van Waterschoot, R. A., Lagas, J. S., Wagenaar, E., van der Kruijssen, C. M., van Herwaarden, A. E., Song, J. Y., Rooswinkel, R. W., van Tellingen, O., Rosing, H., Beijnen, J. H., Schinkel, A. H. Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity. Cancer Res. 2009, 69, 8996-9002.
17. van Herwaarden, A. E., Wagenaar, E., van der Kruijssen, C. M., van Waterschoot, R. A., Smit, J. W., Song, J. Y., van der Valk, M. A., van Tellingen, O., van der Hoorn, J. W., Rosing, H., Beijnen, J. H., Schinkel, A. H. Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism. J. Clin. Invest. 2007, 117, 3583-3592.
18. Kemper, E. M., Verheij, M., Boogerd, W., Beijnen, J. H., van Tellingen, O. Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein. Eur. J. Cancer 2004, 40, 1269-1274.
19. Sparreboom, A., van Asperen, J., Mayer, U., Schinkel, A. H., Smit, J. W., Meijer, D. K., Borst, P., Nooijen, W. J., Beijnen, J. H., van Tellingen, O. Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc. Natl. Acad. Sci. U. S. A. 1997, 94, 2031-2035.
20. Lagas, J. S., Vlaming, M. L ., van Tellingen, O., Wagenaar, E., Jansen, R. S., Rosing, H., Beijnen, J. H., Schinkel, A. H. Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics. Clin. Cancer Res. 2006, 12, 6125-6132.
21. van Waterschoot, R. A., Lagas, J. S., Wagenaar, E., Rosing, H., Beijnen, J. H., Schinkel, A. H. Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel. Int. J. Cancer 2010, 127, 2959-2964.
22. Tang, S. C., Lagas, J. S., Lankheet, N. A., Poller, B., Hillebrand, M. J., Rosing, H., Beijnen, J. H., Schinkel, A. H. Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration. Int. J. Cancer 2012, 130, 223-233.
23. Schinkel, A. H., Wagenaar, E., Mol, C. A., van Deemter, L. P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996 , 97 , 2517-2524.
24. Jonker, J. W., Buitelaar, M., Wagenaar, E., Van Der Valk, M. A., Scheffer, G. L., Scheper, R. J., Plosch, T., Kuipers, F., Elferink, R. P., Rosing, H., Beijnen, J. H., Schinkel, A. H. The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria. Proc. Natl. Acad. Sci. U. S. A. 2002, 99, 15649-15654.
25. Jonker, J. W., Freeman, J., Bolscher, E., Musters, S., Alvi, A. J., Titley, I., Schinkel, A. H., Dale, T. C. Contribution of the ABC transporters Bcrp1 and Mdr1a/1b to the side population phenotype in mammary gland and bone marrow of mice. Stem Cells 2005, 23, 1059-1065.
26. Vlaming, M. L., Mohrmann, K., Wagenaar, E., de Waart, D. R., Elferink, R. P., Lagas, J. S., van Tellingen, O., Vainchtein, L. D., Rosing, H., Beijnen, J. H., Schellens, J. H., Schinkel, A. H. Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice. J. Pharmacol. Exp. Ther. 2006, 318, 319-327.
27. Lagas, J. S., Fan, L., Wagenaar, E., Vlaming, M. L., van Tellingen, O., Beijnen, J. H., Schinkel, A. H. P-glycoprotein (P-gp/ Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide. Clin. Cancer Res. 2010, 16, 130-140.
28. Dai, H., Marbach, P., Lemaire, M., Hayes, M., Elmquist, W. F. Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux. J. Pharmacol. Exp. Ther. 2002, 304, 1085-1092.
29. Tang, S. C., Sparidans, R. W., Cheung, K. L., Fukami, T., Durmus, S., Wagenaar, E., Yokoi, T., van Vlijmen, B. J., Beijnen, J. H., Schinkel, A. H. P-glycoprotein, CYP3A, and plasma carboxylesterase determine brain and blood disposition of the mTOR Inhibitor everolimus (Afinitor) in mice. Clin. Cancer Res. 2014, 20, 3133-3145.
30. Schoemaker, N. E., Rosing, H., Jansen, S., Schellens, J. H., Beijnen, J. H. High-performance liquid chromatographic analysis ofthe anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma. Ther. Drug Monit. 2003, 25, 120-124.
31. Lagas, J. S., Damen, C. W., van Waterschoot, R. A., Iusuf, D., Beijnen, J. H., Schinkel, A. H. P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine. Mol. Pharmacol. 2012, 82, 636-644.
32. Morton, C. L., Iacono, L., Hyatt, J. L., Taylor, K. R., Cheshire, P. J., Houghton, P. J., Danks, M. K., Stewart, C. F., Potter, P. M. Activation and antitumor activity of CPT-11 in plasma esterase-deficient mice. Cancer Chemother. Pharmacol. 2005, 56, 629-636.
33. Pivot, X., Koralewski, P., Hidalgo, J. L., Chan, A., Goncalves, A., Schwartsmann, G., Assadourian, S., Lotz, J. P. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients. Ann. Oncol. 2008, 19, 1547-1552.
34. Mita, A. C., Denis, L. J., Rowinsky, E. K., Debono, J. S., Goetz, A. D., Ochoa, L., Forouzesh, B., Beeram, M., Patnaik, A., Molpus, K., Semiond, D., Besenval, M., Tolcher, A. W. Phase I and pharmacokinetic study of XRP6258 (RPR 116258A), a novel taxane, administered as a 1-h infusion every 3 weeks in patients with advanced solid tumors. Clin. Cancer Res. 2009, 15, 723-730.
35. Duran, G. E., Wang, Y. C., Francisco, E. B., Rose, J. C., Martinez, F. J., Coller, J., Brassard, D., Vrignaud, P., Sikic, B. I. Mechanisms of resistance to cabazitaxel. Mol. Cancer Ther. 2015, 14, 193-201.
36. Ballatore, C., Brunden, K. R., Trojanowski, J. Q., Lee, V. M., Smith, A. B., 3rd, Huryn, D. M. Modulation of protein-protein interactions as a therapeutic strategy for the treatment of neuro-degenerative tauopathies. Curr. Top. Med. Chem. 2011 , 11 , 317-330.
37. Bardelmeijer, H. A., Ouwehand, M., Buckle, T., Huisman, M. T., Schellens, J. H., Beijnen, J. H., van Tellingen, O. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir. Cancer Res. 2002, 62, 6158-6164.
38. van Asperen, J., van Tellingen, O., van der Valk, M. A., Rozenhart, M., Beijnen, J. H. Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A. Clin. Cancer Res. 1998, 4, 2293-2297.
39. Bahar, F. G., Ohura, K., Ogihara, T., Imai, T. Species difference of esterase expression and hydrolase activity in plasma. J. Pharm. Sci. 2012, 101, 3979-3988.
40. Nishimuta, H., Houston, J. B., Galetin, A. Hepatic, intestinal, renal, and plasma hydrolysis of prodrugs in human, cynomolgus monkey, dog, and rat: implications for in vitro-in vivo extrapolation of clearance of prodrugs. Drug Metab. Dispos. 2014, 42, 1522-1531.
41. Iusuf, D., Hendrikx, J. J., van Esch, A., van de Steeg, E., Wagenaar, E., Rosing, H., Beijnen, J. H., Schinkel, A. H. Human OATP1B1, OATP1B3 and OATP1A2 can mediate the in vivo uptake and clearance of docetaxel. Int. J. Cancer 2015, 136, 225-233.
42. van de Steeg, E., van Esch, A., Wagenaar, E., Kenworthy, K. E., Schinkel, A. H. Influence of human OATP1B1, OATP1B3, and OATP1A2 on the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic mice. Clin. Cancer Res. 2013, 19, 821-832.